Ted M Burns
Overview
Explore the profile of Ted M Burns including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
2122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hehir M, Conaway M, St Sauveur A, Feb K, Kolb N, Waheed W, et al.
Muscle Nerve
. 2023 Sep;
69(1):32-39.
PMID: 37676119
Introduction/aims: We developed a patient- and physician-weighted consensus unit called the adverse event unit (AEU) that quantifies and compares adverse event (AE) burden among any group of medications in neurological...
2.
Hehir M, Conaway M, Clark E, Aronzon D, Kolb N, Kolb A, et al.
PLoS One
. 2022 Feb;
17(2):e0262109.
PMID: 35176061
Objective: To design a physician and patient derived tool, the Adverse Event Unit (AEU), akin to currency (e.g. U.S. Dollar), to improve AE burden measurement independent of any particular disease...
3.
Nowak R, Coffey C, Goldstein J, Dimachkie M, Benatar M, Kissel J, et al.
Neurology
. 2021 Dec;
98(4):e376-e389.
PMID: 34857535
Objective: To determine whether rituximab is safe and potentially beneficial, warranting further investigation in an efficacy trial for acetylcholine receptor antibody-positive generalized MG (AChR-Ab+ gMG). Methods: The B-Cell Targeted Treatment...
4.
Placek K, Benatar M, Wuu J, Rampersaud E, Hennessy L, Van Deerlin V, et al.
EMBO Mol Med
. 2020 Dec;
13(1):e12595.
PMID: 33270986
Amyotrophic lateral sclerosis (ALS) is a multi-system disease characterized primarily by progressive muscle weakness. Cognitive dysfunction is commonly observed in patients; however, factors influencing risk for cognitive dysfunction remain elusive....
5.
Crowell J, Burns T
Continuum (Minneap Minn)
. 2020 Oct;
26(5):1392-1406.
PMID: 33003008
The cost of prescription drugs in the United States is rising like never before and has led to an inflection point where clinicians must consider the potential financial damage to...
6.
Burns T, Crowell J, Smith A
Muscle Nerve
. 2020 Jul;
62(5):573-578.
PMID: 32725709
Escalating drug costs place patients at risk for financial toxicity and demand that physicians understand and act on the ethical and economic principles related to drug pricing. This manuscript reviews...
7.
Burns T, Crowell J, Smith A
Muscle Nerve
. 2020 Jul;
62(5):567-572.
PMID: 32725634
Drug prices in the United States have reached astounding heights, negatively impacting patients and society. The vast majority of prescription drug spending is on brand name drugs, which are protected...
8.
Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R, et al.
Neurology
. 2020 May;
95(1):e59-e69.
PMID: 32385188
Objective: To identify preferred neurofilament assays and clinically validate serum neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) as prognostic and potential pharmacodynamic biomarkers relevant to amyotrophic lateral sclerosis (ALS)...
9.
Cutter G, Xin H, Aban I, Burns T, Allman P, Farzaneh-Far R, et al.
Muscle Nerve
. 2019 Sep;
60(6):707-715.
PMID: 31487038
Introduction: The Myasthenia Gravis Patient Registry (MGR) is a voluntary, patient-submitted database dedicated to improve understanding of care/burden of myasthenia gravis (MG). Methods: In this study we present analyses of...
10.
Bjelica B, Peric S, Gwathmey K, Sadjadi R, Bozovic I, Burns T, et al.
J Peripher Nerv Syst
. 2019 Jun;
24(3):247-252.
PMID: 31209940
To date there are only two validations on the Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) questionnaire, both originated from the North America. We sought to translate and validate CAPPRI for...